Q2 2025 Earnings Call Transcript August 7, 2025 Intellia Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

GAAP revenue of $14.2 million for Q2 2025 beat analyst estimates and Revenue more than doubled year over year in the second quarter, beating analyst estimates. Net loss per share (GAAP) narrowed to ...

In July 2025, Novartis Pharmaceuticals announced a phase III study to assess efficacy and safety of crizanlizumab (5 mg/kg) ...

Investors have become quite familiar with the Magnificent Seven, the group of tech giants that reshaped markets with their dominance in AI, cloud computing, and digital ecosystems by driving ...

Its main initiative, NTLA-2001, aims to treat transthyretin amyloidosis, a disease that is currently incurable. Targeting hereditary angioedema (HAE), NTLA-2002 is another promising medication in ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) – Analysts at Cantor Fitzgerald lifted their FY2025 earnings estimates for shares of Intellia Therapeutics in a research note issued to ...

NTLA-2002: NTLA-2002 is a wholly owned, investigational in vivo CRISPR-based therapy designed to knock out the KLKB1 gene in the liver, with the goal of lifelong control of HAE attacks after a ...

Among other items, Intellia announced that it plans to focus its resources on developing drug candidates NTLA-2002 and nex-z and will discontinue development of NTLA-3001, which will result in the ...

No-moat Intellia Therapeutics’ gene editing pipeline is continuing to make progress as it dosed the first patient in its global phase 3 study evaluating NTLA-2002 in hereditary angioedema ...